Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Mechanistic insights into the clinical Y96D mutation with acquired resistance to AMG510 in the KRASG12C
Haiming Zhuang, Jigang Fan, Mingyu Li, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 11

Showing 11 citing articles:

Markov State Models and Molecular Dynamics Simulations Reveal the Conformational Transition of the Intrinsically Disordered Hypervariable Region of K-Ras4B to the Ordered Conformation
Hao Zhang, Duan Ni, Jigang Fan, et al.
Journal of Chemical Information and Modeling (2022) Vol. 62, Iss. 17, pp. 4222-4231
Closed Access | Times Cited: 26
Structural perspectives on recent breakthrough efforts toward direct drugging of RAS and acquired resistance
Jameela Lokhandwala, Tracess Smalley, Timothy H. Tran
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 5
Atomistic Profiling of KRAS Interactions with Monobodies and Affimer Proteins Through Ensemble-Based Mutational Scanning Unveils Conserved Residue Networks Linking Cryptic Pockets and Regulating Mechanisms of Binding, Specificity and Allostery
Mohammed Alshahrani, V S Parikh, Brian Foley, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Closed Access
Research progress on small molecule inhibitors targeting KRAS G12C with acrylamide structure and the strategies for solving KRAS inhibitor resistance
Zhiyan Jiang, Yan Li, Xin Zhou, et al.
Bioorganic & Medicinal Chemistry (2024) Vol. 100, pp. 117627-117627
Closed Access | Times Cited: 4
Direct GDP-KRASG12C inhibitors and mechanisms of resistance: the tip of the iceberg
Joshua C. Rosen, Adrian G. Sacher, Ming‐Sound Tsao
Therapeutic Advances in Medical Oncology (2023) Vol. 15
Open Access | Times Cited: 9
Molecular docking and molecular dynamics simulations reveal the clinical resistance of the gatekeeper mutation V564F of FGFR2 against Infigratinib
Guodong Zheng, Wuxia Liu, Qian Zhang, et al.
Journal of Experimental Nanoscience (2023) Vol. 18, Iss. 1
Open Access | Times Cited: 4
Mechanistic insights into the role of calcium in the allosteric regulation of the calmodulin-regulated death-associated protein kinase
Xiaolong Li, Bo Li, Jun Li, et al.
Frontiers in Molecular Biosciences (2022) Vol. 9
Open Access | Times Cited: 4
Discovery and development of Krazati (adagrasib/MRTX849), a potent, selective, orally bioavailable, covalent KRASG12C(OFF) inhibitor
Adrian L. Gill, M. Marx
Elsevier eBooks (2024), pp. 205-227
Closed Access
LUMAKRAS® (sotorasib)
Nuria Tamayo, Ryan P. Wurz, Brian A. Lanman
Elsevier eBooks (2024), pp. 173-203
Closed Access
Computational revealing Infigratinib resistance to the FGFR2 N549H and N549K mutations
Guanghuan Xu, Bin Wu, Wenqi Liang, et al.
Journal of Experimental Nanoscience (2024) Vol. 20, Iss. 1
Open Access
Innovative design and potential applications of covalent strategy in drug discovery
Tianxi Tang, Jiaxiang Luo, Dan Zhang, et al.
European Journal of Medicinal Chemistry (2024) Vol. 284, pp. 117202-117202
Closed Access
Page 1

Scroll to top